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Introduction
T
he American Diabetes Association
(ADA) has been actively involved in
the development and dissemination
of diabetes care standards, guidelines,
and related documents for many years.
These statements are published in one or
more of the Association’s professional
journals. This supplement contains the
latest update of ADA’s major position
statement, “Standards of Medical Care in
Diabetes,” which contains all of the Asso-
ciation’s key recommendations. In addi-
tion, contained herein are selected position
statements on certain topics not adequately
coveredinthe“Standards.”ADAhopesthat
this is a convenient and important resource
forallhealthcareprofessionalswhocarefor
people with diabetes.
ADA Clinical Practice Recommenda-
tions consist of position statements that
representofﬁcialADAopinionasdenoted
byformalreviewandapprovalbythePro-
fessional Practice Committee and the Ex-
ecutive Committee of the Board of
Directors.Consensusreportsandsystem-
atic reviews are not ofﬁcial ADA
recommendations; however, they are
produced under the auspices of the Asso-
ciation by invited experts. These publica-
tions may be used by the Professional
Practice Committee as source documents
to update the “Standards.”
ADA has adopted the following deﬁ-
nitions for its clinically related reports.
ADA position statement. An ofﬁcial
point of view or belief of the ADA. Posi-
tion statements are issued on scientiﬁc or
medical issues related to diabetes. They
may be authored or unauthored and are
published in ADA journals and other sci-
entiﬁc/medical publications as appropri-
ate.Positionstatementsmustbereviewed
andapprovedbytheProfessionalPractice
Committee and, subsequently, by the
ExecutiveCommitteeoftheBoardofDi-
rectors. ADA position statements are
typically based on a systematic review
or other review of published literature.
They are reviewed on an annual basis
and updated as needed. A list of recent
position statements is included on p. S100
of this supplement.
Systematic review. A balanced review
and analysis of the literature on a scien-
tiﬁc or medical topic related to diabetes.
Effective January 2010, technical reviews
are replaced with systematic reviews, for
which a priori search and inclusion/
exclusion criteria are developed and pub-
lished. The systematic review provides a
scientiﬁc rationale for a position state-
mentandundergoescriticalpeerreview
before submission to the Professional
Practice Committee for approval. A list
of past technical reviews is included on
page S97 of this supplement.
Consensusreport. Acomprehensiveex-
amination by a panel of experts (i.e., con-
sensus panel) of a scientiﬁc or medical
issuerelatedtodiabetes.EffectiveJanuary
2010, consensus statements are renamed
consensus reports. The category will also
includetaskforce,workgroup,andexpert
committee reports. Consensus reports
will not have the Association’s name in-
cluded in the title or subtitle and will in-
clude a disclaimer in the introduction
stating that any recommendations are not
ADA position. A consensus report is typ-
ically developed immediately following a
consensus conference at which presenta-
tions are made on the issue under review.
The statement represents the panel’s col-
lective analysis, evaluation, and opinion
at that point in time based in part on the
conference proceedings. The need for a
consensusreportariseswhencliniciansor
scientists desire guidance on a subject for
which the evidence is contradictory or in-
complete. Once written by the panel, a
consensus report is not subject to subse-
quent review or approval and does not
represent ofﬁcial Association opinion. A
Table 1—ADA evidence-grading system for clinical practice recommendations
Level of
evidence Description
A Clear evidence from well-conducted, generalizable, randomized controlled trials
that are adequately powered, including:
  Evidence from a well-conducted multicenter trial
  Evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling nonexperimental evidence, i.e., the “all or none” rule developed by the
Centre for Evidence-Based Medicine at Oxford
Supportive evidence from well-conducted randomized controlled trials that are
adequately powered, including:
  Evidence from a well-conducted trial at one or more institutions
  Evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies, including:
  Evidence from a well-conducted prospective cohort study or registry
  Evidence from a well-conducted meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies, including:
  Evidence from randomized clinical trials with one or more major or three or
more minor methodological ﬂaws that could invalidate the results
  Evidence from observational studies with high potential for bias (such as case
series with comparison to historical controls)
  Evidence from case series or case reports
Conﬂicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
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The Association’s Professional Prac-
tice Committee is responsible for review-
ing ADA systematic reviews and position
statements, as well as for overseeing revi-
sionsofthelatterasneeded.Appointment
to the Professional Practice Committee is
based on excellence in clinical practice
and/or research. The committee com-
prisesphysicians,diabeteseducators,and
registereddietitianswhohaveexpertisein
a range of areas, including adult and pe-
diatric endocrinology, epidemiology, and
public health, lipid research, hyperten-
sion, and preconception and pregnancy
care. All members of the Professional
Practice Committee are required to dis-
close potential conﬂicts of interest (listed
below).
Grading of scientiﬁc evidence. There
hasbeenconsiderableevolutionintheeval-
uation of scientiﬁc evidence and in the de-
velopment of evidence-based guidelines
since the ADA ﬁrst began publishing prac-
tice guidelines. Accordingly, we developed
a classiﬁcation system to grade the quality
of scientiﬁc evidence supporting ADA
recommendations for all new and revised
ADA position statements.
Recommendations are assigned rat-
ings of A, B, or C, depending on the qual-
ity of evidence (Table 1). Expert opinion
(E) is a separate category for recommen-
dations in which there is as yet no evi-
dence from clinical trials, in which
clinical trials may be impractical, or in
which there is conﬂicting evidence. Rec-
ommendations with an “A” rating are
basedonlargewell-designedclinicaltrials
or well-done meta-analyses. Generally,
these recommendations have the best
chance of improving outcomes when
applied to the population to which they
are appropriate. Recommendations
with lower levels of evidence may be
equally important but are not as well
supported. The level of evidence sup-
porting a given recommendation is
noted either as a heading for a group of
recommendations or in parentheses af-
ter a given recommendation.
Of course, evidence is only one com-
ponentofclinicaldecision-making.Clini-
cians care for patients, not populations;
guidelines must always be interpreted
withtheneedsoftheindividualpatientin
mind. Individual circumstances, such as
comorbid and coexisting diseases, age,
education, disability, and, above all, pa-
tients’ values and preferences, must also
be considered and may lead to different
treatment targets and strategies. Also,
conventional evidence hierarchies, such
as the one adapted by the ADA, may miss
some nuances that are important in dia-
betescare.Forexample,whilethereisex-
cellent evidence from clinical trials
supporting the importance of achieving
glycemic control, the optimal way to
achieve this result is less clear. It is difﬁ-
cult to assess each component of such a
complex intervention.
ADA will continue to improve and
update the Clinical Practice Recommen-
dations to ensure that clinicians, health
plans, and policymakers can continue to
relyonthemasthemostauthoritativeand
current guidelines for diabetes care. Our
Clinical Practice Recommendations are
alsoavailableontheAssociation’swebsite
at www.diabetes.org/diabetescare.
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